Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96HU8
UPID:
DIRA2_HUMAN
Alternative names:
Distinct subgroup of the Ras family member 2
Alternative UPACC:
Q96HU8; B3KVM2
Background:
The GTP-binding protein Di-Ras2, also known as a distinct subgroup of the Ras family member 2, is characterized by its low GTPase activity, predominantly existing in the GTP-bound form. This protein plays a crucial role in cellular signaling pathways, impacting cell growth, differentiation, and survival.
Therapeutic significance:
Understanding the role of GTP-binding protein Di-Ras2 could open doors to potential therapeutic strategies. Its involvement in key cellular processes makes it a significant target for drug discovery, aiming to modulate its activity for therapeutic benefits.